Mass spectrometric studies on the in vivo metabolism and excretion of SIRT1 activating drugs in rat urine, dried blood spots, and plasma samples for doping control purposes

Journal of Pharmaceutical and Biomedical Analysis

Volumn 88, Issue , 2014, Pages 649-659

  Höppner, Sebastian ^a   Delahaut, Philippe ^b   Schänzer, Wilhelm ^a   Thevis, Mario ^a,c  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b CER Groupe   (Belgium)

^c European Monitoring Center for Emerging Doping Agents   (Germany)

Author keywords

DBS; Doping; Metabolism; SRT1720; SRT2104

Indexed keywords

IMIDAZOLE DERIVATIVE; SIRTUIN 1; SRT 12; SRT 14; SRT 1720; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; DOPING; DRIED BLOOD SPOT TESTING; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG URINE LEVEL; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL NOISE RATIO; SINGLE DRUG DOSE; STANDARD; URINALYSIS; URINARY EXCRETION;

DBS; DOPING; METABOLISM; SRT1720; SRT2104;

ADMINISTRATION, ORAL; ANIMALS; CHROMATOGRAPHY, LIQUID; DOPING IN SPORTS; DRIED BLOOD SPOT TESTING; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; IONS; LIQUID-LIQUID EXTRACTION; LIVER; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS; RATS; RATS, WISTAR; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SIRTUIN 1; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY;

EID: 84887506436     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.10.022     Document Type: Article

References (60)

1. Michan S., Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem. J. 2007, 404:1-13.
2. Yuan H., Marmorstein R. Structural basis for sirtuin activity and inhibition. J. Biol. Chem. 2012, 287:42428-42435.
3. Revollo J.R., Li X. The ways and means that fine tune Sirt1 activity. Trends Biochem. Sci. 2013, 38:160-167.
4. Guo X., Williams J.G., Schug T.T., Li X. DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. J. Biol. Chem. 2010, 285:13223-13232.
5. Liu X., Wang D., Zhao Y., Tu B., Zheng Z., Wang L., Wang H., Gu W., Roeder R.G., Zhu W.G. Methyltransferase Set7/9 regulates p53 activity by interacting with Sirtuin 1 (SIRT1). Proc. Natl. Acad. Sci. USA 2011, 108:1925-1930.
6. Yang Y., Fu W., Chen J., Olashaw N., Zhang X., Nicosia S.V., Bhalla K., Bai W. SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat. Cell Biol. 2007, 9:1253-1262.
7. Kim E.J., Kho J.H., Kang M.R., Um S.J. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol. Cell 2007, 28:277-290.
8. Kim J.E., Chen J., Lou Z. DBC1 is a negative regulator of SIRT1. Nature 2008, 451:583-586.
9. Houtkooper R.H., Canto C., Wanders R.J., Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr. Rev. 2010, 31:194-223.
10. Silva J.P., Wahlestedt C. Role of Sirtuin 1 in metabolic regulation. Drug Discov. Today 2010, 15:781-791.
11. Rodgers J.T., Lerin C., Haas W., Gygi S.P., Spiegelman B.M., Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005, 434:113-118.
12. Xiong S., Salazar G., Patrushev N., Alexander R.W. FoxO1 mediates an autofeedback loop regulating SIRT1 expression. J. Biol. Chem. 2011, 286:5289-5299.
13. Okazaki M., Iwasaki Y., Nishiyama M., Taguchi T., Tsugita M., Nakayama S., Kambayashi M., Hashimoto K., Terada Y. PPARbeta/delta regulates the human SIRT1 gene transcription via Sp1. Endocr. J. 2010, 57:403-413.
14. Handschin C., Spiegelman B.M. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr. Rev. 2006, 27:728-735.
15. Gross D.N., van den Heuvel A.P., Birnbaum M.J. The role of FoxO in the regulation of metabolism. Oncogene 2008, 27:2320-2336.
16. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
17. Bass T.M., Weinkove D., Houthoofd K., Gems D., Partridge L. Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech. Ageing Dev. 2007, 128:546-552.
18. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
19. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., Jin L., Boss O., Perni R.B., Vu C.B., Bemis J.E., Xie R., Disch J.S., Ng P.Y., Nunes J.J., Lynch A.V., Yang H., Galonek H., Israelian K., Choy W., Iffland A., Lavu S., Medvedik O., Sinclair D.A., Olefsky J.M., Jirousek M.R., Elliott P.J., Westphal C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.
20. Feige J.N., Lagouge M., Canto C., Strehle A., Houten S.M., Milne J.C., Lambert P.D., Mataki C., Elliott P.J., Auwerx J. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008, 8:347-358.
21. Zarse K., Schmeisser S., Birringer M., Falk E., Schmoll D., Ristow M. Differential effects of resveratrol and SRT1720 on lifespan of adult Caenorhabditis elegans. Horm. Metab. Res. 2010, 42:837-839.
22. de Cabo R., Ellis J., Sinclair D., Minor R.K. Sirtuin activating compounds, resveratrol and SRT1720, extend healthspan and lifespan of C57BL6 male mice. FEBS J. 2011, 278. 44-44.
23. Minor R.K., Baur J.A., Gomes A.P., Ward T.M., Csiszar A., Mercken E.M., Abdelmohsen K., Shin Y.K., Canto C., Scheibye-Knudsen M., Krawczyk M., Irusta P.M., Martin-Montalvo A., Hubbard B.P., Zhang Y., Lehrmann E., White A.A., Price N.L., Swindell W.R., Pearson K.J., Becker K.G., Bohr V.A., Gorospe M., Egan J.M., Talan M.I., Auwerx J., Westphal C.H., Ellis J.L., Ungvari Z., Vlasuk G.P., Elliott P.J., Sinclair D.A., de Cabo R. SRT1720 improves survival and healthspan of obese mice. Sci. Rep. 2011, 1:70.
24. Stunkel W., Campbell R.M. Sirtuin 1 (SIRT1): the misunderstood HDAC. J. Biomol. Screen. 2011, 16:1153-1169.
25. Canto C., Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 2009, 20:98-105.
26. Pacholec M., Bleasdale J.E., Chrunyk B., Cunningham D., Flynn D., Garofalo R.S., Griffith D., Griffor M., Loulakis P., Pabst B., Qiu X., Stockman B., Thanabal V., Varghese A., Ward J., Withka J., Ahn K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 2010, 285:8340-8351.
27. Beher D., Wu J., Cumine S., Kim K.W., Lu S.C., Atangan L., Wang M. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des. 2009, 74:619-624.
28. Dai H., Kustigian L., Carney D., Case A., Considine T., Hubbard B.P., Perni R.B., Riera T.V., Szczepankiewicz B., Vlasuk G.P., Stein R.L. SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J. Biol. Chem. 2010, 285:32695-32703.
29. Hubbard B.P., Gomes A.P., Dai H., Li J., Case A.W., Considine T., Riera T.V., Lee J.E., Lamming S.Y.E.D.W., Pentelute B.L., Schuman E.R., Stevens L.A., Ling A.J., Armour S.M., Michan S., Zhao H., Jiang Y., Sweitzer S.M., Blum C.A., Disch J.S., Ng P.Y., Howitz K.T., Rolo A.P., Hamuro Y., Moss J., Perni R.B., Ellis J.L., Vlasuk G.P., Sinclair D.A. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013, 339:1216-1219.
30. Kugel S., Mostoslavsky R. SIRT1 activators: the evidence STACks up. Aging (Albany NY) 2013, 5:142-143.
31. Lakshminarasimhan M., Rauth D., Schutkowski M., Steegborn C. Sirt1 activation by resveratrol is substrate sequence-selective. Aging (Albany NY) 2013, 5:151-154.
32. Picard F., Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado De Oliveira R., Leid M., McBurney M.W., Guarente L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004, 429:771-776.
33. Menzies K.J., Hood D.A. The role of SirT1 in muscle mitochondrial turnover. Mitochondrion 2012, 12:5-13.
34. Banks A.S., Kon N., Knight C., Matsumoto M., Gutierrez-Juarez R., Rossetti L., Gu W., Accili D. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 2008, 8:333-341.
35. Lin J., Wu H., Tarr P.T., Zhang C.Y., Wu Z., Boss O., Michael L.F., Puigserver P., Isotani E., Olson E.N., Lowell B.B., Bassel-Duby R., Spiegelman B.M. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002, 418:797-801.
36. Huber K., Superti-Furga G. After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders. Bioorg. Med. Chem. 2011, 19:3616-3624.
37. Blum C.A., Ellis J.L., Loh C., Ng P.Y., Perni R.B., Stein R.L. SIRT1 modulation as a novel approach to the treatment of diseases of aging. J. Med. Chem. 2011, 54:417-432.
38. Qi Y., Davis M.L., Lainez E.O., Cote A.M., Johnson M.O., Gagne D.J., Vlasuk G.P., Ellis J.L., Suri V. SRT2104, a Novel Small Molecule SIRT1 Activator Ameliorates Insulin Resistance and Promotes Glucose Utilization Measured under a Hyperinsulinemic-Euglycemic Clamp by Enhancing Both Glycolysis and Carbohydrate Oxidation in Mice Fed a High Fat Diet 2011, Available: http://www.sirtrispharma.com/pdfs/ADA-11-Poster-Qi-et-al.pdf.
39. Suri V., Qi Y., Davis M., Cote A., Lainez E., Johnson M., Hirsch M., Gagne D., Ellis J., Mathai G. Metabolomic Analysis Reveals Profound Impact of SIRT1 Activators on Carbohydrate and Lipid Oxidation in Multiple Tissues available 2011, http://www.sirtrispharma.com/pdfs/Cell-Aging-Poster-11-Suri-et-al.pdf.
40. Yoshizaki T., Schenk S., Imamura T., Babendure J.L., Sonoda N., Bae E.J., Oh D.Y., Lu M., Milne J.C., Westphal C., Bandyopadhyay G., Olefsky J.M. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E419-E428.
41. Villalba J.M., de Cabo R., Alcain F.J. A patent review of sirtuin activators: an update. Expert. Opin. Ther. Pat. 2012, 22:355-367.
42. Lee D.H. Sirt1 as a new therapeutic target in metabolic and age-related diseases. Chonnam Med. J. 2010, 46:67.
43. Vu C.B., Bemis J.E., Disch J.S., Ng P.Y., Nunes J.J., Milne J.C., Carney D.P., Lynch A.V., Smith J.J., Lavu S., Lambert P.D., Gagne D.J., Jirousek M.R., Schenk S., Olefsky J.M., Perni R.B. Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators. J. Med. Chem. 2009, 52:1275-1283.
44. Nayagam V.M., Wang X., Tan Y.C., Poulsen A., Goh K.C., Ng T., Wang H., Song H.Y., Ni B., Entzeroth M., Stunkel W. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J. Biomol. Screen. 2006, 11:959-967.
45. Ellis J.L., Gagne D.J., Suri V., Cermak J.M., Lyng G.D., Guarente L.P., Vlasuk G.P. SRT2104, a Novel and Selective Small Molecule SIRT1 Activator, Inhabits DSS-Induced Colitis in a SIRT1-Dependent Manner 2011, Available: http://www.sirtrispharma.com/pdfs/WIC-11-Poster-Ellis-et-al.pdf.
46. Hoffmann E., Wald J., Lavu S., Roberts J., Beaumont C., Haddad J., Elliott P., Westphal C., Jacobson E. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br. J. Clin. Pharmacol. 2013, 75:186-196.
47. Libri V., Brown A.P., Gambarota G., Haddad J., Shields G.S., Dawes H., Pinato D.J., Hoffman E., Elliot P.J., Vlasuk G.P., Jacobson E., Wilkins M.R., Matthews P.M. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS ONE 2012, 7:e51395.
48. Höppner S., Schänzer W., Thevis M. Fragmentation studies of SIRT1-activating drugs and their detection in human plasma for doping control purposes. Rapid Commun. Mass Spectrom. 2013, 27:35-50.
49. Höppner S., Schänzer W., Thevis M. Mass spectrometric studies on the in vitro generated metabolites of SIRT1 activating drugs for doping control purposes. J. Mass Spectrom. 2013, 48:830-843.
50. Kuuranne T., Leinonen A., Schänzer W., Kamber M., Kostiainen R., Thevis M. Aryl-propionamide-derived selective androgen receptor modulators: liquid chromatography-tandem mass spectrometry characterization of the in vitro synthesized metabolites for doping control purposes. Drug Metab. Dispos. 2008, 36:571-581.
51. Beuck S., Schänzer W., Thevis M. Investigation of the in vitro metabolism of the emerging drug candidate S107 for doping-preventive purposes. J. Mass Spectrom. 2011, 46:112-130.
52. International Conference of Harmonisation 2004, Available: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf.
53. Kromidas S. Validierung in der Analytik 2011, Wiley-VCH, Weinheim.
54. Bonfiglio R., King R.C., Olah T.V., Merkle K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun. Mass Spectrom. 1999, 13:1175-1185.
55. Guddat S., Solymos E., Orlovius A., Thomas A., Sigmund G., Geyer H., Thevis M., Schänzer W. High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry multi-target approach. Drug Test. Anal. 2011, 3:836-850.
56. Thomas A., Guddat S., Kohler M., Krug O., Schänzer W., Petrou M., Thevis M. Comprehensive plasma-screening for known and unknown substances in doping controls. Rapid Commun. Mass Spectrom. 2010, 24:1124-1132.
57. Thomas A., Geyer H., Guddat S., Schänzer W., Thevis M. Dried blood spots (DBS) for doping control analysis. Drug Test. Anal. 2011, 3:806-813.
58. Thomas A., Geyer H., Schanzer W., Crone C., Kellmann M., Moehring T., Thevis M. Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole/Orbitrap mass spectrometer. Anal. Bioanal. Chem. 2012, 403:1279-1289.
59. Masimirembwa C.M., Bredberg U., Andersson T.B. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin. Pharmacokinet. 2003, 42:515-528.
60. Park B.K., Kitteringham N.R., O'Neill P.M. Metabolism of fluorine-containing drugs. Annu. Rev. Pharmacol. Toxicol. 2001, 41:443-470.